feed,title,long_url,short_url
Benzinga,Adaptimmune's Stock Trades Higher As TCR Therapy Shows Initial Durability In Soft Tissue Cancer Settings,https://benzinga.com/general/biotech/21/05/21212125/adaptimmunes-stock-trades-higher-as-tcr-therapy-shows-initial-durability-in-soft-tissue-cancer-se,https://j.mp/3fwLEUB
